Clinical Trials Logo

Clinical Trial Summary

This study is to evaluate the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas.


Clinical Trial Description

This trial is aimed at evaluating the effectiveness of ultra-low dose Bevacizumab plus Temozolomide for recurrent high-grade gliomas. And, this trial is approved by medical ethics committee of Hebei Yanda Hospital.Researchers will conduct thsi trial from 2015/05 to 2018/05, and 30 recurrent high-grade glioma patients will be recruited. Patients who are recruited will get treatment of ultra-low dose Bevacizumab plus Temozolomide in ether Hebei Yanda Hospital or Beijing Tiantan hospital, and get follow-ups from clinicians. ;


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT02416999
Study type Interventional
Source Hebei Yanda Hospital
Contact Nan Ji, MD
Phone +86 13910713896
Email neurochina@gmail.com
Status Not yet recruiting
Phase N/A
Start date May 2015
Completion date May 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04588987 - Neoadjuvant Carilizumab and Apatinib for Recurrent High-Grade Glioma Phase 2
Terminated NCT05394558 - AsiDNA Children, Adolescents and Young Adults Phase 1/Phase 2
Not yet recruiting NCT02333513 - A Study to Evaluate the Safety and Effectiveness of PCV Chemotherapy in Patients With Recurrent High-grade Glioma With IDH1/2 Mutation N/A
Recruiting NCT05737212 - Studying the Safety, Efficacy, and Pharmacokinetic Characteristics of BNCT in Patients With Recurrent High-grade Gliomas Phase 1/Phase 2
Recruiting NCT04822805 - A Study of Anlotinib in the Treatment of Recurrent High-grade Glioma Phase 2